文献速递胸部肿瘤

日本ALK阳性非小细胞肺癌患者接受克唑替尼治疗后药物性间质性肺病的发生及其危险因素

Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib.
PubMed 文献 · J Thorac Oncol · 2018-12-03

日本开展克唑替尼上市后监测,纳入2012年5月至2014年12月期间接受克唑替尼治疗的ALK阳性非小细胞肺癌患者,观察52周,由5名专家组成的间质性肺病独立评审委员会判定。安全性分析集2028例,克唑替尼相关间质性肺病发生率为5.77%,其中3.45%为3级及以上。

要点

  • 克唑替尼相关间质性肺病发生率为5.77%,3级及以上为3.45%。
  • 41.9%的间质性肺病发生在开始克唑替尼后4周内,69.2%发生在8周内。
  • 年龄≥55岁、ECOG评分2-4、吸烟史、既往或合并间质性肺病、合并胸腔积液为显著危险因素。

核心结论

  • 克唑替尼相关间质性肺病发生率为5.77%,其中3级及以上为3.45%。
  • 具有年龄≥55岁、ECOG评分2-4、吸烟史、既往或合并间质性肺病、合并胸腔积液等危险因素的患者应谨慎监测间质性肺病发生。
  • 临床医生应关注严重间质性肺病的风险。

研究设计与样本

  • 日本开展的克唑替尼上市后监测,旨在获取安全性和有效性信息。
  • 目标患者为2012年5月至2014年12月入组期间接受克唑替尼治疗的全体ALK阳性非小细胞肺癌患者。
  • 观察期为52周。
  • 间质性肺病发生情况由5名医学专家组成的间质性肺病独立评审委员会进行专家分析。
  • 安全性分析集包括2028例患者。

主要发现

  • 安全性分析集2028例中,超过半数患者(56.4%)为非吸烟者。
  • 克唑替尼相关间质性肺病发生率为5.77%,3级及以上为3.45%。
  • 克唑替尼相关间质性肺病中观察到伴或不伴弥漫性肺泡损伤模式的肺水肿样阴影,发生率为0.39%,但未能确定其与预后的因果关系。
  • 41.9%的间质性肺病发生在开始克唑替尼给药后4周内,69.2%发生在8周内。
  • 年龄≥55岁、ECOG评分2-4、吸烟史、既往或合并间质性肺病、合并胸腔积液被统计学判定为克唑替尼诱导间质性肺病的显著危险因素。

临床怎么用

  • 作者认为,对于具有上述任一危险因素的非小细胞肺癌患者,克唑替尼治疗应在谨慎监测间质性肺病发生的情况下应用。
  • 作者认为,临床医生应关注严重间质性肺病的风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The study objective was to determine the incidence and characteristics of drug-induced interstitial lung disease (ILD) associated with an orally available small-molecule tyrosine kinase inhibitor, crizotinib, in a real-world clinical setting. METHODS: Post-marketing surveillance was performed in Japan to obtain information on the safety and efficacy of crizotinib. Target patients included all patients with anaplastic lymphoma kinase-positive NSCLC who received crizotinib during the enrollment period between May 2012 and December 2014. The observation period was 52 weeks. Expert analysis of the ILD incidence was performed by an ILD independent review committee composed of five medical specialists. RESULTS: The safety analysis set included 2028 patients, and more than half of the patients (56.4%) were nonsmokers. The incidence of ILD associated with crizotinib therapy was 5.77%; and 3.45% patients showed grade 3 or greater. Pulmonary edema-like shadows with or without diffuse alveolar damage pattern were observed in crizotinib-associated ILD (incidence: 0.39%), but a causal relationship with the prognosis could not be identified. ILD developed within 4 weeks from initiation of crizotinib administration in 41.9% and within 8 weeks in 69.2% of the patients. Age 55 years or older, Eastern Cooperative Oncology Group performance status 2-4, smoking history, previous or concomitant ILD, and comorbid pleural effusion were statistically determined as significant risk factors for crizotinib-induced ILD. CONCLUSIONS: Crizotinib therapy should be applied to the NSCLC patients with any of above risk factors under a cautious monitoring for ILD occurrence, and clinicians should pay attention to the risks of severe ILD.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gemma A, Kusumoto M, Kurihara Y, et al. Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib. J Thorac Oncol. 2018. PMID: 30521972. doi:10.1016/j.jtho.2018.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。